Interim findings to be presented at leading U.S. academic conferences
[by Ji, Yong Jun] Verismo Therapeutics (hereinafter referred to as Verismo), the U.S. subsidiary of HLB Innovation, announced on September 11 that the Phase 1 clinical trial of ‘SynKIR-110,’ a next-generation chimeric antigen receptor T-cell (CAR-T) therapy candidate for solid tumors, is progressing as planned.
The company reported that SynKIR-110 is currently being administered to patients at major U.S. cancer centers, including the Hospital of the University of Pennsylvania and MD Anderson Cancer Center, and is in the final stages of Cohort 4. Verismo plans to present interim data from the Phase 1 바카라 에볼루션 trial on the safety and preliminary efficacy of SynKIR-110 at major U.S. academic conferences later this year or in the first half of 2026.
SynKIR-110 is being developed for the treatment of relapsed or refractory ovarian cancer, cholangiocarcinoma, and mesothelioma. The ongoing Phase 1 바카라 에볼루션 trial is designed to evaluate safety, assess preliminary efficacy, and determine the recommended Phase 2 dose (RP2D). These indications represent areas of high unmet medical need. Obtaining confirmatory evidence in Phase 2 바카라 에볼루션 studies would support a new drug application to the U.S. Food and Drug Administration (FDA), potentially enabling a faster market entry compared to existing therapies.
To accelerate the Phase 2 바카라 에볼루션 trial, Verismo is establishing GMP (Good Manufacturing Practice) production capabilities and preparing for manufacturing through technology transfer to a contract manufacturing organization (CMO) located in the eastern United States.
"The rapid expansion of patient dosing in solid tumor 바카라 에볼루션 trials is a strong signal of the high potential and 바카라 에볼루션 demand for SynKIR-110 at leading cancer centers, and it underscored the capabilities of our internal team in the CMC and 바카라 에볼루션 development," said Bryan Kim, CEO of HLB Innovation.
Meanwhile, leveraging its experience with Kymriah, the world's first commercialized CAR-T therapy, Verismo has developed its proprietary ‘KIR-CAR’ platform technology to address ‘T-cell exhaustion,’ a key limitation of existing CAR-T therapies. Existing commercially available CAR-T therapies are prone to excessive energy consumption and functional decline due to their unnatural receptor structure. By contrast, Verismo's KIR-CAR platform incorporates the KIR receptor, naturally expressed on NK cells, into T cells, enabling CAR-T cells to rest and sustain their function for extended periods in the body.
Verismo is developing SynKIR-110 as a solid tumor treatment candidate while also conducting a multi-center Phase 1 바카라 에볼루션 trial in the United States for SynKIR-310, a blood cancer treatment candidate. In December 2024, recognizing the technological value of SynKIR-310, Verismo entered into a strategic investment and partnership with the Institute for Follicular Lymphoma Innovation (IFLI) and plans to release initial Phase 1 바카라 에볼루션 trial data for blood cancer in the coming year.